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tumor volume reduction than meningiomas that were 3 (8.94% 
vs. 7.59% per year). These results suggest that a notable 
tumor volume reduction is predicted within 3 to 4 years after 
irradiation, and thereafter, the tumor volume decreases at a 
slower rate for more than 10 years. 
Conclusions: The quantitative volumetric analysis of the 
pattern of tumor volume reduction in response to irradiation 
gives an insight into the radiobiological nature of intracranial 
meningiomas after conventionally fractionated radiation 
therapy. 
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Purpose/Objective: To evaluate the safety and efficacy of 
postoperative hyperfractionated concomitant boost proton 
radiotherapy for supratentorial glioblastoma multiforme 
(GBM). 
Materials and Methods: Forty-six patients with supratentorial 
GBM were treated by high dose (96.6 GyE) photon and proton 
radiotherapy. There were 24 males and 22 females, and the 
median age was 58 years old (range: 24 - 76). The KPS were 
50, 60, 70, 80, 90, and 100 % in 1,4,10,12,11, and 8 patients, 
respectively. The median MIB-1 index was 30.8 (range:5.1-
70). The gross total resection, subtotal resection, and partial 
resection were performed for 2, 29, and 15 patients, 
respectively. Photon beam were delivered to the T(2)-
weighted high area on magnetic resonance imaging (MRI) in 
the morning (50.4 Gy in 28 fractions). More than 6 hours 
later, proton beams were delivered to the enhanced area 
plus a 10-mm margin in the first half of the protocol (23.1 
GyE in 14 fractions) and to the enhanced volume in the latter 
half (23.1 GyE in 14 fraction). Concurrent chemotherapy with 
nimustine hydrochloride (80 mg/m2) during first and fourth 
weeks or daily temozolomide (75mg/m2) was administrated 
in 23 and 23 patients, respectively. 
Results: The overall survival rates after 1 and 2 years were 
80.4% and 44.6%, respectively. The median survival period 
was 21.1 months (95% CI: 13.0-29.1). The 1- and 2-year 
progression-free survival rates were 34.8% and 8.7%, 
respectively. There was no significant survival difference 
between nimustine hydrochloride and temozolomide groups 
(p=0.33). Acute toxicity was mainly hematologic and was 
controllable. Late radiation necrosis and 
leukoencephalopathy were seen in 11 and 2 patients, 
respectively, but all patients with radiation necrosis were 
controlled by necrotomy and medical therapy including 
bevacizumab administration. 
Conclusions: Hyperfractionated concomitant boost proton 
radiotherapy (96.6 GyE in 56 fractions) with nimustine 
hydrochloride or temozolomide for GBM was tolerable and 
beneficial for patients with supratentorial GBM. 
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Purpose/Objective: Bevacizumab has been extensively 
studied in recurrent high-grade glioma patients as first and 
second-line therapy. To date, there is a limited number of 
reports on its epidemiological use in an unselected patient 
cohort. Therefore, we report on our experience on a large 
number of patients treated at our institution. 
Materials and Methods: After receiving standard 
radiotherapy (with or without TMZ) patients with recurrent 
malignant glioma were treated with bevacizumab (10mg/kg 
intravenously, q2w), either as mono/combination therapy 
(27.2%), upfront (12%) or in combination to re-irradiation, 
with (22.4%) or without maintenance therapy (38.4%). Median 
prescribed radiation dose during re-treatment was 36Gy, 
conventionally fractionated. 
Results: 125 patients were included in this retrospective 
analysis with proven high-grade glioma. Median age was 50 
years and median KPS at re-treatment 80. Median number of 
bevacizumab cycles preceding progression was three, with 
median four cumulative cycles. 
Median follow-up after initiation of bevacizumab treatment 
was 37 months and median overall survival since first 
diagnosis 29 months (WHO grades III + IV). Median post-
recurrence survival was 9 months, median post-recurrence 
PFS 5 months (PFS-6 36.5%). 
Univariate testing revealed that sex, WHO grade, time 
interval from initial diagnosis, MGMT methylation, IDH 
mutation, combination with irinotecan and age had no 
significant influence on neither PRS nor PR-PFS. Significant 
factors according to PRS/PR-PFS were a KPS < 70 (PR-PFS 
median 3 vs. 6 months, p=0.02; PRS median 5 vs. 10 months, 
p=0.007), a larger number of bevacizumab cycles and the 
respective treatment group (most favorable: re-RT + 
bevacizumab + maintenance therapy). 
Conclusions: Bevacizumab appears to be a valuable agent in 
recurrent malignant glioma therapy. Activity of monotherapy 
was seen, especially in combination with reirradiation. KPS 
was the most important predictor for both PRS and PR-PFS. 
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Purpose/Objective: Glioblastoma (GBM) is a very aggressive 
and radioresistant tumor associated with bad prognosis. 
Current trends in GBM treatments are based on a 
